sar425899 dual agonist glp-1 glucagon sanofi First clinical PET study measuring the receptor occupancy of a GLP1/ receptor is now published Glucagonlike Peptide-1 Receptor Imaging in
Description
doi: 10.1007/s40265-014-0321-6 183 ChalasaniNYounossiZLavineJECharltonMCusiKRinellaMet al
71 These data, together with the finding of no effect of prior weight-reduction strategies on hard outcomes in HF, signify very likely beneficial effects of GLP-1RAs that are independent of weight loss
In a new study published yesterday in JAMA Ophthalmology , researchers looked at retrospective electronic health record network data comprising patients with and without diabetes who received prescriptions for GLP-1 drugs, metformin, insulin or sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Shatha Taha, GP practitioner specialising in longevity and wellness
[DOI] [PubMed] [Google Scholar] 127.Liu Y., Han X., Bian Z., Peng Y., You Z., Wang Q., Chen X., Qiu D., Ma X
The ACCORD Study Group
